[1]
Vanhaesebroeck, B.; Waterfield, M.D. Signaling by distinct classes of phosphoinositide 3-kinases. Exp. Cell Res., 1999, 253(1), 239-254.
[2]
Vanhaesebroeck, B.; Guillermet-Guibert, J.; Graupera, M.; Bilanges, B. The emerging mechanisms of isoform-specific PI3K signalling. Nat. Rev. Mol. Cell Biol., 2010, 11(5), 329-341.
[3]
Vanhaesebroeck, B.; Stephens, L.; Hawkins, P. PI3K signalling: the path to discovery and understanding. Nat. Rev. Mol. Cell Biol., 2012, 13(3), 195-203.
[4]
Vivanco, I.; Sawyers, C.L. The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat. Rev. Cancer, 2002, 2(7), 489-501.
[5]
Cantley, L.C. The phosphoinositide 3-kinase pathway. Science, 2002, 296(5573), 1655-1657.
[6]
Huang, C-H.; Mandelker, D.; Schmidt-Kittler, O.; Samuels, Y.; Velculescu, V.E.; Kinzler, K.W.; Vogelstein, B.; Gabelli, S.B.; Amzel, L.M. The structure of a human p110 alpha/p85 alpha complex elucidates the effects of oncogenic PI3K alpha mutations. Science, 2007, 318(5857), 1744-1748.
[7]
Samuels, Y.; Wang, Z.H.; Bardelli, A.; Silliman, N.; Ptak, J.; Szabo, S.; Yan, H.; Gazdar, A.; Powell, D.M.; Riggins, G.J.; Willson, J.K.V.; Markowitz, S.; Kinzler, K.W.; Vogelstein, B.; Velculescu, V.E. High frequency of mutations of the PIK3CA gene in human cancers. Science, 2004, 304(5670), 554-554.
[8]
Samuels, Y.; Diaz, L.A.; Schmidt-Kittler, O.; Cummins, J.M.; DeLong, L.; Cheong, I.; Rago, C.; Huso, D.L.; Lengauer, C.; Kinzler, K.W.; Vogelstein, B.; Velculescu, V.E. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell, 2005, 7(6), 561-573.
[9]
Zhao, L.; Vogt, P.K. Helical domain and kinase domain mutations in p110 alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc. Natl. Acad. Sci. USA, 2008, 105(7), 2652-2657.
[10]
Liu, P.; Cheng, H.; Roberts, T.M.; Zhao, J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov., 2009, 8(8), 627-644.
[11]
Miled, N.; Yan, Y.; Hon, W-C.; Perisic, O.; Zvelebil, M.; Inbar, Y.; Schneidman-Duhovny, D.; Wolfson, H.J.; Backer, J.M.; Williams, R.L. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science, 2007, 317(5835), 239-242.
[12]
Cully, M.; You, H.; Levine, A.J.; Mak, T.W. Beyond PTEN mutations: The PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer, 2006, 6(3), 184-192.
[13]
Carracedo, A.; Pandolfi, P.P. The PTEN-PI3K pathway: Of feedbacks and cross-talks. Oncogene, 2008, 27(41), 5527-5541.
[14]
Hayakawa, M.; Kaizawa, H.; Moritomo, H.; Koizumi, T.; Ohishi, T.; Okada, M.; Ohta, M.; Tsukamoto, S-i.; Parker, P.; Workman, P.; Waterfield, M. Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110 alpha inhibitors. Bioorg. Med. Chem., 2006, 14(20), 6847-6858.
[15]
Hayakawa, M.; Kaizawa, H.; Kawaguchi, K-i.; Ishikawa, N.; Koizumi, T.; Ohishi, T.; Yamano, M.; Okada, M.; Ohta, M.; Tsukamoto, S-i.; Raynaud, F.I.; Waterfield, M.D.; Parker, P.; Workman, P. Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110 alpha inhibitors. Bioorg. Med. Chem., 2007, 15(1), 403-412.
[16]
Hayakawa, M.; Kaizawa, H.; Moritomo, H.; Koizumi, T.; Ohishi, T.; Yamano, M.; Okada, M.; Ohta, M.; Tsukamoto, S.; Raynaud, F.I.; Workman, P.; Waterfield, M.D.; Parker, P. Synthesis and biological evaluation of pyrido[3′,2′:4,5]furo[3,2-d]pyrimidine derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg. Med. Chem. Lett., 2007, 17(9), 2438-2442.
[17]
Hayakawa, M.; Kawaguchi, K-I.; Kaizawa, H.; Tomonobu, K.; Ohishi, T.; Yamano, M.; Okada, M.; Ohta, M.; Tsukamoto, S-i.; Raynaud, F.I.; Parker, P.; Workman, P.; Waterfield, M.D. Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110 alpha inhibitors. Bioorg. Med. Chem., 2007, 15(17), 5837-5844.
[18]
Raynaud, F.I.; Eccles, S.; Clarke, P.A.; Hayes, A.; Nutley, B.; Alix, S.; Henley, A.; Di-Stefano, F.; Ahmad, Z.; Guillard, S.; Bjerke, L.M.; Kelland, L.; Valenti, M.; Patterson, L.; Gowan, S.; Brandon, A.D.H.; Hayakawa, M.; Kaizawa, H.; Koizumi, T.; Ohishi, T.; Patel, S.; Saghir, N.; Parker, P.; Waterfield, M.; Workman, P. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res., 2007, 67(12), 5840-5850.
[19]
Kendall, J.D.; Rewcastle, G.W.; Frederick, R.; Mawson, C.; Denny, W.A.; Marshall, E.S.; Baguley, B.C.; Chaussade, C.; Jackson, S.P.; Shepherd, P.R. Synthesis, biological evaluation and molecular modelling of sulfonohydrazides as selective PI3K p110 alpha inhibitors. Bioorg. Med. Chem., 2007, 15(24), 7677-7687.
[20]
Knight, S.D.; Adams, N.D.; Burgess, J.L.; Chaudhari, A.M.; Darcy, M.G.; Donatelli, C.A.; Luengo, J.I.; Newlander, K.A.; Parrish, C.A.; Ridgers, L.H.; Sarpong, M.A.; Schmidt, S.J.; Van Aller, G.S.; Carson, J.D.; Diamond, M.A.; Elkins, P.A.; Gardiner, C.M.; Garver, E.; Gilbert, S.A.; Gontarek, R.R.; Jackson, J.R.; Kershner, K.L.; Luo, L.; Raha, K.; Sherk, C.S.; Sung, C-M.; Sutton, D.; Tummino, P.J.; Wegrzyn, R.J.; Auger, K.R.; Dhanak, D. Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of Rapamycin. ACS Med. Chem. Lett., 2010, 1(1), 39-43.
[21]
Kendall, J.D.; Giddens, A.C.; Tsang, K.Y.; Frederick, R.; Marshall, E.S.; Singh, R.; Lill, C.L.; Lee, W-J.; Kolekar, S.; Chao, M.; Malik, A.; Yu, S.; Chaussade, C.; Buchanan, C.; Rewcastle, G.W.; Baguley, B.C.; Flanagan, J.U.; Jamieson, S.M.F.; Denny, W.A.; Shepherd, P.R. Novel pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors: Exploring the benzenesulfonohydrazide SAR. Bioorg. Med. Chem., 2012, 20(1), 58-68.
[22]
Kendall, J.D.; O’Connor, P.D.; Marshall, A.J.; Frédérick, R.; Marshall, E.S.; Lill, C.L.; Lee, W.J.; Kolekar, S.; Chao, M.; Malik, A.; Yu, S.; Chaussade, C.; Buchanan, C.; Rewcastle, G.W.; Baguley, B.C.; Flanagan, J.U.; Jamieson, S.M.F.; Denny, W.A.; Shepherd, P.R. Discovery of pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors. Bioorg. Med. Chem., 2012, 20(1), 69-85.
[23]
Sabbah, D.A.; Simms, N.A.; Wang, W.; Dong, Y.; Ezell, E.L.; Brattain, M.G.; Vennerstrom, J.L.; Zhong, H.A. N-Phenyl-4-hydroxy-2-quinolone-3-carboxamides as selective inhibitors of mutant H1047R phosphoinositide-3-kinase (PI3Kα). Bioorg. Med. Chem., 2012, 20(24), 7175-7183.
[24]
Sweidan, K.; Engelmann, J.; Abu Rayyan, W.; Sabbah, D.; Abu Zarga, M.; Al-Qirim, T.; Al-Hiari, Y.; Abu Sheikha, G.; Shattat, G. Synthesis and preliminary biological evaluation of new heterocyclic carboxamide models. Lett. Drug Des. Discov., 2015, 12(5), 417-429.
[25]
Sabbah, D.A.; Saada, M.; Khalaf, R.A.; Bardaweel, S.; Sweidan, K.; Al-Qirim, T.; Al-Zughier, A.; Halim, H.A.; Sheikha, G.A. Molecular modeling based approach, synthesis and cytotoxic activity of novel benzoin derivatives targeting phosphoinostide 3-kinase (PI3Kα). Bioorg. Med. Chem. Lett., 2015, 25(16), 3120-3124.
[26]
Sweidan, K.; Sabbah, D.A.; Bardaweel, S.; Dush, K.A.; Sheikha, G.A.; Mubarak, M.S. Computer-aided design, synthesis and biological evaluation of new indole-2-carboxamide derivatives as PI3Kα/EGFR inhibitors. Bioorg. Med. Chem. Lett., 2016, 26(11), 2685-2690.
[27]
Sweidan, K.; Sabbah, D.A.; Bardaweel, S.; Abu-Sheikha, G.; Al-Qirim, T.; Salih, H.; El-Abadelah, M.M.; Mubarak, M.S.; Voelter, W. Facile synthesis, characterization and cytotoxicity study of new 3-(indol-2-yl)bicyclotetrazatridecahexaens. Can. J. Chem., 2017, 95(8), 858-862.
[28]
Sabbah, D.A.; Hishmah, B.; Sweidan, K.; Bardaweel, S.; AlDamen, M.; Zhong, H.A.; Abu-Khalaf, R.; Ibrahim, A.H.; Al-Qirim, T.; Abu-Sheikha, G.; Mubarak, M.S. Structure-based design: Synthesis, x-ray crystallography and biological evaluation of n-substituted-4-hydroxy-2-quinolone-3-carboxamides as potential cytotoxic agents. Anticancer. Agents Med. Chem., 2018, 18, 263-276.
[29]
Kong, D.; Yamori, T. Advances in development of phosphatidylinositol 3-kinase inhibitors. Curr. Med. Chem., 2009, 16(22), 2839-2854.
[30]
Sabbah, D.A.; Brattain, M.G.; Zhong, H. Dual inhibitors of PI3K/mTOR or mTOR-selective inhibitors: Which way shall we go? Curr. Med. Chem., 2011, 18(36), 5528-5544.
[31]
Rodon, J.; Dienstmann, R.; Serra, V.; Tabernero, J. Development of PI3K inhibitors: Lessons learned from early clinical trials. Nat. Rev. Clin. Oncol., 2013, 10(3), 143-153.
[32]
Sabbah, D.A.; Hu, J.; Zhong, H.A. Advances in the development of class I phosphoinositide 3-kinase (PI3K). Curr. Top. Med. Chem., 2016, 16(13), 1413-1426.
[33]
Sabbah, D.A.; Simms, N.A.; Brattain, M.G.; Vennerstrom, J.L.; Zhong, H. Biological evaluation and docking studies of recently identified inhibitors of phosphoinositide-3-kinases. Bioorg. Med. Chem. Lett., 2012, 22(2), 876-880.
[34]
MOE. The Molecular Operating Environment; Chemical Computing Group, Inc Montreal: Quebec, Canada, 2016.
[35]
Sabbah, D.A.; Al-Tarawneh, F.; Talib, W.; Sweidan, K.; Bardaweel, S.; Al-Shalabi, E.; Zhong, H.A.; Sheikha, G.A.; Khalaf, R.A.; Mubarak, M.S. Benzoin schiff bases: Design, synthesis and biological evaluation as potential antitumor agents. Med. Chem., 2018, 14, 695-708.
[36]
Zhu, Y.; Wang, A.; Liu, M.C.; Zwart, A.; Lee, R.Y.; Gallagher, A.; Wang, Y.; Miller, W.R.; Dixon, J.M.; Clarke, R. Estrogen receptor alpha positive breast tumors and breast cancer cell lines share similarities in their transcriptome data structures. Int. J. Oncol., 2006, 29(6), 1581-1589.
[37]
Talib, W.H.; Mahasneh, A.M. Combination of Ononis hirta and Bifidobacterium longum decreases syngeneic mouse mammary tumor burden and enhances immune response. J. Cancer Res. Ther., 2012, 8(3), 417.
[38]
Talib, W.H. Consumption of garlic and lemon aqueous extracts combination reduces tumor burden by angiogenesis inhibition, apoptosis induction, and immune system modulation. Nutr. J., 2017, 43, 89-97.
[39]
Talib, W.H. Regressions of breast carcinoma syngraft following treatment with piperine in combination with thymoquinone. Sci. Pharm., 2017, 85(3), 27.
[40]
Raja, S.P.; Arunkumar, R.; Sivakamasundari, V.; Sharmila, G.; Elumalai, P.; Suganthapriya, E.; Brindha, M.A.; Senthil, K.K.; Arunakaran, J. Anti-proliferative and apoptosis inducing effect of nimbolide by altering molecules involved in apoptosis and IGF signalling via PI3K/Akt in prostate cancer (PC-3) cell line. Cell Biochem. Funct., 2014, 32(3), 217-228.
[41]
Du, J-Q.; Wu, J.; Zhang, H-J.; Zhang, Y-H.; Qiu, B-Y.; Wu, F.; Chen, Y-H.; Li, J-Y.; Nan, F-J.; Ding, J-P.; Li, J. Isoquinoline-1,3,4-trione derivatives inactivate caspase-3 by generation of reactive oxygen species. J. Biol. Chem., 2008, 283(44), 30205-30215.
[43]
Stender, J.D.; Nwachukwu, J.C.; Kastrati, I.; Kim, Y.; Strid, T.; Yakir, M.; Srinivasan, S.; Nowak, J.; Izard, T.; Rangarajan, E.S. Structural and molecular mechanisms of cytokine-mediated endocrine resistance in human breast cancer cells. Mol. Cell, 2017, 65(6), 1122-1135.
[44]
Sabbah, D.A.; Vennerstrom, J.L.; Zhong, H. Docking Studies on isoform-specific inhibition of phosphoinositide-3-kinases. J. Chem. Inf. Model., 2010, 50(10), 1887-1898.
[45]
Sabbah, D.A.; Hishmah, B.; Sweidan, K.; Bardaweel, S.; AlDamen, M.; Zhong, H.A.; Khalaf, R.A.; Hasan, I.A.; Al-Qirim, T.; Sheikha, G.A.; Mubarak, M.S. Structure-based design: synthesis, X-ray crystallography, and biological evaluation of N-substituted-4-hydroxy-2-quinolone-3-carboxamides as potential PI3Kα inhibitors. Anticancer. Agents Med. Chem., 2017. In Press
[46]
Schrödinger. Protein Preparation Wizard, Maestro, Macromodel, and QPLD-dock; 97204 2016.
[47]
Brattain, M.G.; Levine, A.E.; Chakrabarty, S.; Yeoman, L.C.; Willson, J.K.V.; Long, B. Heterogeneity of human colon carcinoma. Cancer Metastasis Rev., 1984, 3(3), 177-191.
[48]
Lauring, J.; Park, B.H.; Wolff, A.C. The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer. J. Natl. Compr. Canc. Netw., 2013, 11(6), 670-678.
[49]
Wu, G.; Xing, M.; Mambo, E.; Huang, X.; Liu, J.; Guo, Z.; Chatterjee, A.; Goldenberg, D.; Gollin, S.M.; Sukumar, S.; Trink, B.; Sidransky, D. Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res., 2005, 7(5), R609-R616.
[50]
Beaver, J.A.; Gustin, J.P.; Yi, K.H.; Rajpurohit, A.; Thomas, M.; Gilbert, S.F.; Rosen, D.M.; Park, B.H.; Lauring, J. PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system. Clin. Cancer Res., 2013, 19(19), 5413-5422.
[51]
She, Q-B.; Chandarlapaty, S.; Ye, Q.; Lobo, J.; Haskell, K.M.; Leander, K.R.; DeFeo-Jones, D.; Huber, H.E.; Rosen, N. Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One, 2008, 3(8), e3065.
[52]
Weigelt, B.; Warne, P.H.; Downward, J. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene, 2011, 30(29), 3222-3233.
[53]
Zardavas, D.; Phillips, W.A.; Loi, S. PIK3CA mutations in breast cancer: Reconciling findings from preclinical and clinical data. Breast Cancer Res., 2014, 16(1), 201.
[54]
Ebi, H.; Costa, C.; Faber, A.C.; Nishtala, M.; Kotani, H.; Juric, D.; Della Pelle, P.; Song, Y.; Yano, S.; Mino-Kenudson, M.; Benes, C.H.; Engelman, J.A. PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1. Proc. Natl. Acad. Sci. USA, 2013, 110(52), 21124-21129.
[55]
Sanchez, C.G.; Ma, C.X.; Crowder, R.J.; Guintoli, T.; Phommaly, C.; Gao, F.; Lin, L.; Ellis, M.J. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res., 2011, 13(2), R21.
[56]
Spangle, J.M.; Dreijerink, K.M.; Groner, A.C.; Cheng, H.; Ohlson, C.E.; Reyes, J.; Lin, C.Y.; Bradner, J.; Zhao, J.J.; Roberts, T.M.; Brown, M. PI3K/AKT Signaling regulates H3K4 methylation in breast cancer. Cell Rep, 2016, 15(12), 2692-2704.
[57]
Kataoka, Y.; Mukohara, T.; Shimada, H.; Saijo, N.; Hirai, M.; Minami, H. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann. Oncol., 2010, 21(2), 255-262.
[58]
Sabine, V.S.; Crozier, C.; Brookes, C.L.; Drake, C.; Piper, T.; van de Velde, C.J.; Hasenburg, A.; Kieback, D.G.; Markopoulos, C.; Dirix, L. Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study. J. Clin. Oncol., 2014, 32(27), 2951-2958.
[59]
Liu, J-L.; Gao, G-R.; Zhang, X.; Cao, S-F.; Guo, C-L.; Wang, X.; Tong, L-J.; Ding, J.; Duan, W-H.; Meng, L-H. DW09849, a Selective phosphatidylinositol 3-Kinase (PI3K) inhibitor, prevents PI3K signaling and preferentially inhibits proliferation of cells containing the oncogenic mutation p110α (H1047R). J. Pharm. Exp. Ther., 2014, 348(3), 432-441.
[60]
Simi, L.; Pratesi, N.; Vignoli, M.; Sestini, R.; Cianchi, F.; Valanzano, R.; Nobili, S.; Mini, E.; Pazzagli, M.; Orlando, C. High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am. J. Clin. Pathol., 2008, 130(2), 247-253.
[61]
Schneck, H.; Blassl, C.; Meier-Stiegen, F.; Neves, R.P.; Janni, W.; Fehm, T.; Neubauer, H. Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients. Mol. Oncol., 2013, 7(5), 976-986.
[62]
Rabi, T.; Huwiler, A.; Zangemeister-Wittke, U. AMR-Me inhibits PI3K/Akt signaling in hormone-dependent MCF-7 breast cancer cells and inactivates NF-κB in hormone-independent MDA-MB-231 cells. Mol. Carcinog., 2014, 53(7), 578-588.
[63]
Board, R.E.; Thelwell, N.J.; Ravetto, P.F.; Little, S.; Ranson, M.; Dive, C.; Hughes, A.; Whitcombe, D. Multiplexed assays for detection of mutations in PIK3CA. Clin. Chem., 2008, 54(4), 757-760.
[64]
Blair, B.G.; Wu, X.; Zahari, M.S.; Mohseni, M.; Cidado, J.; Wong, H.Y.; Beaver, J.A.; Cochran, R.L.; Zabransky, D.J.; Croessmann, S. A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations. Proteomics, 2015, 15(2-3), 318-326.
[65]
Song, J.; Yang, Q.; Lv, F.; Liu, L.; Wang, S. Visual detection of DNA mutation using multicolor fluorescent coding. ACS Appl. Mater. Interfaces, 2012, 4(6), 2885-2890.
[66]
Aksamitiene, E.; Kholodenko Bn Fau-Kolch, W.; Kolch, W. Fau-Hoek, J.B.; Hoek Jb Fau-Kiyatkin, A.; Kiyatkin, A. PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells. Cell. Signal., 2010, 22(9), 1369-1378.
[67]
Li, G-Y.; Jung, K.H.; Lee, H.; Son, M.K.; Seo, J.; Hong, S-W.; Jeong, Y.; Hong, S.; Hong, S-S. A novel imidazopyridine derivative, HS-106, induces apoptosis of breast cancer cells and represses angiogenesis by targeting the PI3K/mTOR pathway. Cancer Lett., 2013, 329(1), 59-67.
[68]
Juric, D.; Castel, P.; Griffith, M.; Griffith, O.L.; Won, H.H.; Ellis, H.; Ebbesen, S.H.; Ainscough, B.J.; Ramu, A.; Iyer, G. Convergent loss of PTEN leads to clinical resistance to a PI (3) K α inhibitor. Nature, 2015, 518(7538), 240-244.
[69]
Bilbao, P.S.; Santillán, G.; Boland, R. ATP stimulates the proliferation of MCF-7 cells through the PI3K/Akt signaling pathway. Arch. Biochem. Biophys., 2010, 499(1-2), 40-48.
[70]
Park, S.K.; Hwang Ys Fau-Park, K-K.; Park Kk Fau-Park, H-J.; Park Hj Fau-Seo, J.Y.; Seo Jy Fau-Chung, W-Y.; Chung, W.Y. Kalopanaxsaponin A inhibits PMA-induced invasion by reducing matrix metalloproteinase-9 via PI3K/Akt- and PKCdelta-mediated signaling in MCF-7 human breast cancer cells. Carcinogenesis, 2009, 30, 1225-1233.
[71]
Mireuta, M.; Darnel, A.; Pollak, M. IGFBP-2 expression in MCF-7 cells is regulated by the PI3K/AKT/mTOR pathway through Sp1 induced increase in transcription. Growth Factors, 2010, 28(4), 243-255.
[72]
Ebi, H.; Costa, C.; Faber, A.C.; Nishtala, M.; Kotani, H.; Juric, D.; Della Pelle, P.; Song, Y.; Yano, S.; Mino-Kenudson, M.; Benes, C.H.; Engelman, J.A. PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1. Proc. Natl. Acad. Sci., 2013, 110(52), 21124-21129.
[73]
Baselga, J. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. Oncologist, 2011, 16(S1), 12-19.
[74]
Friesner, R.A.; Banks, J.L.; Murphy, R.B.; Halgren, T.A.; Klicic, J.J.; Mainz, D.T.; Repasky, M.P.; Knoll, E.H.; Shelley, M.; Perry, J.K.; Shaw, D.E.; Francis, P.; Shenkin, P.S. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem., 2004, 47(7), 1739-1749.
[75]
Friesner, R.A.; Murphy, R.B.; Repasky, M.P.; Frye, L.L.; Greenwood, J.R.; Halgren, T.A.; Sanschagrin, P.C.; Mainz, D.T. Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem., 2006, 49(21), 6177-6196.
[76]
Sabbah, D.A.; Vennerstrom, J.L.; Zhong, H.A. Binding selectivity studies of phosphoinositide 3-kinases using free energy calculations. J. Chem. Inf. Model., 2012, 52, 3213-3224.
[77]
Sweidan, K.; Sabbah, D.A.; Engelmann, J.; Abdel-Halim, H.; Abu Sheikha, G. Computational docking studies of novel heterocyclic carboxamides as potential PI3Kα inhibitors. Lett. Drug Des. Discov., 2015, 12(10), 856-863.
[78]
Sabbah, D.A.; Sweidan, K. Molecular docking studies of novel thiosemicarbazone-based indoles as potential PI3Kalpha inhibitors. Lett. Drug Des. Discov., 2017, 14(11), 1252-1258.
[79]
Barsanti, P.A.; Aversa, R.J.; Jin, X.; Pan, Y.; Lu, Y.; Elling, R.; Jain, R.; Knapp, M.; Lan, J.; Lin, X.; Rudewicz, P.; Sim, J.; Taricani, L.; Thomas, G.; Xiao, L.; Yue, Q. Structure-based drug design of novel potent and selective tetrahydropyrazolo[1,5-a]pyrazines as ATR inhibitors. ACS Med. Chem. Lett., 2015, 6(1), 37-41.
Download PDF Flyer